Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital(TM) PCR High Complexity Assays
MWN-AI** Summary
Biodesix, Inc. (NYSE: BDSX), a prominent diagnostics solutions provider, has announced an expanded partnership with Bio-Rad Laboratories to develop advanced droplet digital PCR (ddPCR) assays, particularly for oncology applications. Under this agreement, Biodesix will spearhead the development, clinical validation, and regulatory submissions for in vitro diagnostic (IVD) assays that facilitate the sensitive detection of genomic markers. Utilizing Bio-Rad's ddPCR technology on the QX600 platform, the first assay to be validated will be the ddPLEX ESR1 Mutation Detection Assay, crucial for detecting ESR1 mutations in patients with advanced HR+/HER2- breast cancer. The assay can provide high sensitivity and quantification of mutations from circulating tumor DNA (ctDNA), which is significant given the efficacy of new therapies like oral selective estrogen receptor degraders (SERDs) that target these mutations.
Post-validation, Biodesix plans to offer the ESR1 test as a service through its accredited CLIA-CAP laboratory, serving both clinical customers and biopharmaceutical firms working on targeted therapeutics. The company aims to secure CMS reimbursement for this assay, indicating its commitment to making the technology accessible.
According to Biodesix CEO Scott Hutton, the demand for rapid, sensitive assays reflecting the importance of ESR1 mutations in breast cancer treatment is significant. Bio-Rad’s VP of Product Management, Steve Kulisch, affirmed the successful collaboration between the two companies in enhancing clinical diagnostics, particularly in cancer detection.
Both Biodesix and Bio-Rad will present further insights into their research and development initiatives at the upcoming AMP conference in Boston from November 11-15, 2025. This partnership not only underscores the importance of precision medicine but also aims to enhance cancer treatment outcomes.
MWN-AI** Analysis
Biodesix, Inc. (NYSE: BDSX) has made a strategic move by expanding its partnership with Bio-Rad Laboratories to develop innovative high complexity assays aimed at cancer diagnostics, specifically leveraging the Droplet Digital™ PCR (ddPCR™) technology. This collaboration focuses on the ESR1 mutation detection assay, which is becoming increasingly important in managing HR+/HER2- advanced breast cancer. The anticipated regulatory clearance and subsequent commercialization of this assay are set to position Biodesix favorably in the oncology diagnostics market, which is experiencing robust demand for precision medicine solutions.
Investors should consider several factors when evaluating Biodesix’s market trajectory following this announcement. First, the ongoing healthcare shift towards personalized treatment necessitates highly sensitive and specific diagnostic tools, effectively catering to this need through the validated ESR1 assays. The move also demonstrates Biodesix's commitment to remaining agile and responsive in a competitive market, enhancing its product offerings from lung diagnostics to broader oncology applications.
Moreover, with the potential for Medicare reimbursement, the financial viability of these assays could lead to increased adoption among clinical and biopharma partners, directly impacting Biodesix’s revenue streams. As the company prepares to showcase detailed R&D progress at the upcoming AMP conference, stakeholders should monitor how the broader market reacts to this collaboration and any new data presented that can further validate the efficacy of these tests.
In summary, Biodesix’s strategic partnership with Bio-Rad could provide significant long-term growth potential in an increasingly important sector of oncology diagnostics. Investors may want to keep an eye on the developments from the upcoming conferences and the subsequent uptake of validated assays in clinical settings, which could drive share price performance upwards as market demand for precision oncology solutions continues to rise.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad’s QX600 platform. Following regulatory clearance, Biodesix will manufacture and distribute dedicated specimen collection kits for the developed assays.
The first assays to be validated under the agreement include Bio-Rad’s ddPLEX ESR1 Mutation Detection Assay. ESR1 testing is becoming critical in HR+/HER2- advanced breast cancer due to the clinically demonstrated survival benefits from a new generation of therapy called oral selective estrogen receptor degraders (SERDs). The ddPLEX ESR1 Mutation assay will enable highly sensitive detection and absolute quantification of multiple ESR1 mutations from ctDNA samples.
Once validated, the ESR1 assay will be offered as a test service at Biodesix’ accredited CLIA-CAP laboratory for biopharma customers to support the development of targeted therapeutics, as well as for clinical customers to support cancer treatment monitoring. Biodesix will also seek reimbursement for this assay through Centers for Medicare & Medicaid Services (CMS).
“The emergence of ESR1 mutations as biomarkers for breast cancer has had a significant impact on the oncology market, leading to an increased global demand for rapid, sensitive assays,” said Scott Hutton, CEO, Biodesix. “We are proud to expand our partnership with Bio-Rad through this new agreement, demonstrating how our combined capabilities in mutation detection can address clinical needs with speed and precision, and opening doors to personalized, data-driven medicine.”
“Through our long-standing relationship with Biodesix we have effectively delivered both clinical and research-based applications of our ddPCR technology for non-small cell lung cancer, as part of its Lung Diagnostics portfolio,” commented Steve Kulisch, VP Product Management, Life Science Group, Bio-Rad Laboratories. “Validation of our ddPLEX ESR1 kits will further expand our combined capabilities in clinical diagnostics, increasing access to sensitive biomarker detection for advanced breast cancer.”
At the upcoming AMP conference, Nov 11-15, Boston, MA , both companies will be providing more detail on their R&D visions, partnerships, and commercial roadmaps:
- Bio-Rad Laboratories Corporate Workshop , Nov 12, at 8:00 am ET
- Biodesix Corporate Workshop , Nov 12, at 4:00 pm ET
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
natalie.stdenis@biodesix.com
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
chris.brinzey@icrhealthcare.com
(339) 970-2843
FAQ**
How will the expanded partnership between Biodesix Inc. BDSX and Bio-Rad enhance the development of genomic assays for oncology applications, particularly in breast cancer detection?
What regulatory steps does Biodesix Inc. BDSX plan to take for the ESR1 Mutation Detection Assay, and how might this impact its market readiness?
In what ways is Biodesix Inc. BDSX preparing to seek reimbursement through CMS for the new assay, and what implications does this have for overall business growth?
How does the expansion of Biodesix Inc. BDSX's capabilities in mutation detection align with the increasing demand for personalized medicine in oncology?
**MWN-AI FAQ is based on asking OpenAI questions about Biodesix Inc. (NASDAQ: BDSX).
NASDAQ: BDSX
BDSX Trading
-1.82% G/L:
$18.64 Last:
89,688 Volume:
$18.51 Open:
